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Introduction
Treatment results of diffuse large B- cell lymphoma 
(DLBCL) have significantly improved after the introduc-
tion of immunotherapy with the monoclonal CD20 anti-
body rituximab, added to traditional chemotherapy 
regimens [1, 2]. Recently, an association between levels 
of vitamin D and lymphoma mortality has been reported 
for patients with DLBCL [3]. Data from the German 
RICOVER- 60 study actually indicated that vitamin D 
deficiency is a negative prognostic factor for elderly patients 
with DLBCL, treated with rituximab- containing chemo-
therapy (R- CHOP) [4]. Similarly, low serum vitamin D 
levels were identified as negative prognostic factor for 
survival in a retrospective analysis of cohorts of patients 
with follicular lymphoma (FL) [5].
The main blood circulation form of vitamin D is 
25- hydroxyvitamin D3 [25(OH)D], and its level is a good 
indicator of vitamin D status. Vitamin D deficiency, defined 
as a serum 25(OH)D level below 10 ng/mL, is very 
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Abstract
Vitamin D deficiency has been reported to be a negative prognostic factor in 
elderly patients with aggressive B- cell lymphomas. In vitro data suggest that 
vitamin D supplementation may enhance rituximab- mediated cytotoxicity. We 
prospectively assessed 25- hydroxyvitamin D [25(OH)D] levels at diagnosis in a 
cohort of 155 patients with aggressive B- cell lymphomas of whom 128 had 
diffuse large B- cell lymphoma (DLBCL) not otherwise specified. 25(OH)D levels 
were deficient (<20 ng/mL) in 105 (67%), insufficient (20–29 ng/mL) in 32 
(21%), and normal (≥30 ng/mL) in 18 (12%) patients with a seasonal variation. 
Patient characteristics associated with lower 25(OH)D levels were poor perfor-
mance status, overweight, B- symptoms, elevated LDH, lower albumin and hemo-
globin levels. As a result of a change in practice pattern, 116 patients received 
vitamin D3 (cholecalciferol) supplementation that included a loading phase with 
daily replacement and subsequent maintenance phase with a weekly dose of 
25,000 IU until end of treatment. This resulted in a significant increase in 
25(OH)D levels, with normalization in 56% of patients. We analyzed the impact 
of 25(OH)D levels on event- free survival in patients treated with Rituximab- 
CHOP. 25(OH)D levels below 20 ng/mL at diagnosis and IPI were independently 
associated with inferior EFS. Moreover, patients with normalized 25(OH)D levels 
following supplementation showed better EFS than patients with persistently 
deficient/insufficient 25(OH)D levels. Our study provides the first evidence that 
achievement of normal 25(OH)D levels after vitamin D3 supplementation is 
associated with improved outcome in patients with DLBCL and deficient/insuf-
ficient 25(OH)D levels when receiving rituximab- based treatment.
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common in the elderly population, and this is mainly 
explained by low dietary vitamin D intake and the lack 
of sufficient sunlight exposure [6]. A growing body of 
evidence indicates that vitamin D deficiency may play a 
role in the development of common cancers, although a 
recent meta- analysis did not find an association between 
risk for non- Hodgkin lymphoma (NHL) and vitamin D 
deficiency [7–9].
Vitamin D deficiency is well known for its musculo-
skeletal complications [10]. However, vitamin D receptors 
(VDR) are also present on a large variety of extraskeletal 
cell types, including cells of the immune system, where 
vitamin D has been shown to play a role in both innate 
and adaptive immune responses [11, 12]. Antibody- 
mediated cytotoxicity appears to be a major mechanism 
by which rituximab exerts its B- cell depleting activity [13]. 
In this context, vitamin D supplementation has been shown 
to enhance rituximab- mediated cytotoxicity in vitro [14]. 
It is unknown at present whether these mechanisms are 
active as well during treatment of lymphoma patients.
The Institute of Medicine (IOM) in the U.S. recom-
mended a dietary intake of vitamin D 600–800 U/day 
for the general population [15]. Guidelines targeting 
patients recommend higher supplementation doses [16]. 
Supplementation studies are mainly limited to elderly 
people, where efficacy of the regimen is usually assessed 
after 4–6 months or longer [17]. Although supplementa-
tion may help to improve vitamin D status in the long 
run, there is currently no consensus on how to achieve 
this target rapidly, especially in cases of severe vitamin 
D deficiency.
The time required to achieve 25(OH)D concentrations 
in the normal range could be a critical issue in the context 
of NHL treatment. We aimed at rapid normalization of 
vitamin D levels to increase rituximab- efficacy early on 
during therapy. We therefore applied an intensive sup-
plementation regimen with a daily loading phase of 
25,000 IU vitamin D3, tailored to the degree of deficiency, 
followed by a maintenance phase of 25,000 IU once weekly 
till the end of immunotherapy. The aim of our study 
was to develop a practical regimen of oral substitution 
of vitamin D3 (cholecalciferol) that would enable rapid 
improvement of vitamin D deficiency, and maintenance 
of normal levels during treatment with rituximab- 
containing regimens. A secondary objective was to analyze 
for clinical benefits of vitamin D replacement.
Subjects and Methods
Patient characteristics
We studied 155 patients (89 females, 66 males) with a 
median age of 65 years, diagnosed with aggressive B- cell 
lymphoma and treated at the Department of Hematology 
of the Catholic University of the Sacred Heart, Gemelli 
Foundation, in Rome between September 2013 and June 
2016. Histology was: DLBCL not otherwise specified (NOS) 
(n = 128), primary mediastinal large B- cell lymphoma 
(n = 9), B- cell lymphoma, unclassifiable- intermediate 
between DLBCL and Burkitt lymphoma (n = 8), T- cell/
histiocyte- rich DLBCL (n = 4), and other forms (n = 6), 
according to the 2008 WHO classification [18]. All patients 
were treated with rituximab- containing chemotherapy. The 
standard regimen was R- CHOP (rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisolone) given for 
six cycles of CHOP and eight cycles of rituximab, with 
reduction in doxorubicin by 50% in 12 patients and omis-
sion in 26 elderly unfit patients [1, 2].
The study was approved by our institutional review 
board and conducted according to the Declaration of 
Helsinki. All patients provided written consent.
Measurement of serum 25- hydroxyvitamin 
D [25(OH)D] levels
Serum samples for vitamin D quantification were collected 
before the first day of immune- chemotherapy as pretreat-
ment control samples. Follow- up samples were then 
obtained on the first visit following the 1–2 week loading 
phase, and at least 10 days after the final loading dose 
of cholecalciferol. This interval was chosen because previ-
ous studies showed that about 10 days are required to 
convert 90–100% of the absorbed cholecalciferol into 
25(OH)D [19].
25(OH)D was assayed in the central laboratory of the 
Academic Hospital A. Gemelli, Rome, in a blinded fashion 
and in a single batch and measured in patients’ sera using 
a standardized clinical assay, the DiaSorin LIAISON 25- 
OH Vitamin D TOTAL, a fully automated sensitive immu-
noassay that uses a recombinant fusion construct of the 
vitamin D receptor ligand- binding domain for specific 
capture of 25(OH)D. The dynamic range of the assay is 
4.0–150 ng/mL. The lowest value in the laboratory report 
was <7.0 ng/mL, and for statistical purposes, values 
<7.0 ng/mL were scored as 7.0 ng/mL. For the purpose 
of analysis, 25(OH)D levels were defined according to 
three conditions: deficient (<20 ng/mL), insufficient 
 (20–29 ng/mL), and normal (≥30 ng/mL) [20].
Vitamin D supplementation
Patients with 25(OH)D levels lower than 30 ng/mL were 
candidates for vitamin D supplementation. As practice pat-
tern changed over time, 27 patients with 25(OH) levels below 
30 ng/mL were left without supplementation (Table S1). 
Cholecalciferol (vitamin D3) was used for vitamin D 
272 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
S. Hohaus et al.Vitamin D in Aggressive B- cell Lymphomas
supplementation and was taken orally as liquid solution, 
poured on a piece of bread to enhance compliance. As dose 
guidelines for rapid loading were not available, we designed 
a pragmatic dose- escalation schedule that was considered 
safe to conduct as part of regular patient care (Fig. 1, Table 
S1). To minimize the risk of oversupplementation, the first 
group of patients (regimen 1, n = 35) was treated with a 
weekly dose of 25,000 IU vitamin D3. Once laboratory results 
showed that this dose did not induce hypercalcemia, and 
that 25(OH)D levels had only modestly increased with rarely 
hitting the target level of normal (≥30 ng/mL), we added 
a loading phase with 25,000 IU vitamin D3 daily for 1 week. 
Preliminary data confirmed that patients with severe defi-
ciency defined by very low 25(OH)D levels (<10 ng/mL) 
did not reach the target of normal 25(OH)D levels with 
the 1 week loading dose. We then increased the duration 
of daily vitamin D3 supplementation to 2 weeks in this 
patient group. Following the initial cholecalciferol load, the 
treatment was continued using a maintenance dose of 
25,000 IU weekly, until completion of treatment, including 
six cycles of R- CHOP and two additional rituximab doses 
at 375 mg/m2, for a total of 21 weeks. At each cycle, patient 
calcium levels were measured. These regimens correspond 
to a total cholecalciferol dose of 175,000 IU in the 1- week 
and 350,000 units in the 2- week schedule during the loading 
phase, and of 500,000 IU during the maintenance phase of 
eight rituximab- CHOP cycles.
Statistical analysis
Results are expressed as median values ± SD. As 25(OH)
D levels show seasonal variations, we analyzed pretreat-
ment samples according to the season: (1) winter: January 
through March (2) spring: April through June, (3) 
summer: July through September, and (4) fall: October 
through December. Wilcoxon signed- rank test was used 
for two- sample comparisons of 25(OH)D levels according 
to dichotomized patient characteristics, and the Kruskal–
Wallis test, when there were more than two groups.
Changes in 25(OH)D levels following the loading phase 
were analyzed by paired, two- sided t- tests. To enable calcula-
tion procedures, 25(OH)D below the assay’s detection limit 
was given a value of 7 ng/mL. Multivariate logistic regression 
analysis was used to identify the variables that might predict 
the response to cholecalciferol loading dose. Variables included 
for this analysis were: age, body mass index (BMI), sup-
plementation regimen, and baseline serum 25(OH)D.
The primary survival end point was event- free survival 
(EFS), with progression during treatment, lack of complete 
remission at the end of first- line treatment, relapse and 
death from any cause counted as events. Survival curves 
were estimated using the Kaplan–Meier product limit 
method. Log- rank tests were used to analyze for differ-
ences in EFS. Cox regression was used for multivariate 
analysis of EFS including dichotomized (25/OH)D levels 
and the international prognostic score (IPI) (score 0–2 
vs. 3–5). A P < 0.05 was considered statistically significant. 
Computations were performed using the Stata 10.0 soft-
ware (Stata Corp., College Station, TX).
Results
Analysis of 25(OH)D levels in patients with 
aggressive B- cell lymphomas and 
associations with patient characteristics
The median 25(OH)D level at diagnosis, before start of 
therapy, was 14 ng/mL (range: <7–101 ng/mL) in 155 
Figure 1. Supplementation with vitamin D3 during rituximab- containing chemotherapy. Three different vitamin D3 (cholecalciferol) regimens were 
applied. Regimen 1 consisted in weekly administration of 25,000 IU vitamin D3. In regimen 2 and 3, patients started with a loading phase of vitamin 
D3 25,000 IU daily for 7 or 14 days, respectively, and then continued with 25,000 IU weekly till the end of therapy.
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patients with aggressive B- cell lymphomas (Fig. 2A). 
25(OH)D levels were deficient (<20 ng/mL) in 105 patients 
(67%), insufficient (20–29 ng/mL) in 32 patients (55%), 
and normal (≥30–100 ng/mL) in 18 patients (12%) 
(Fig. 2B).
Looking at patient characteristics, 25(OH)D levels were 
lower in patients with reduced performance status 
(ECOG ≥ 2) (P = 0.002), overweight (body mass 
index > 25 kg/m2), P = 0.05], presence of B- symptoms 
(P = 0.05), albumin <4 g/L (P = 0.003), hemoglobin 
below 10 g/dL (P = 0.01), and elevated LDH (P = 0.0007) 
(Table 1). In addition, there was a significant seasonal 
variation, with lowest 25(OH)D levels after winter, and 
highest levels after summer (P = 0.009) (Table 1, Fig. 2C).
Correction of 25(OH)D levels with different 
supplementation regimens
We next considered whether oral supplementation with 
vitamin D3 (cholecalciferol) would rapidly restore 25(OH)
D levels to normal range, and changed our practice 
pattern to supplement vitamin D3. As a consequence of 
this change, a total of 116 patients received oral sup-
plementation with cholecalciferol. A supplementation regi-
men of 25,000 IU once weekly was used in a group of 
35 patients. The increase in 25(OH)D level was modest 
(median increase by 1.3- fold after a median of 3 months, 
n = 21 patients, Table 2). We therefore designed a sup-
plementation regimen that started with a loading phase 
consisting of a 1- week course of daily vitamin D sup-
plementation (regimen 2), that we extended to 2 weeks 
in patients with severely deficient levels (<10 ng/mL) 
(regimen 3). The loading phase was followed by a main-
tenance phase of once weekly vitamin D3 administration 
(Fig. 1). This resulted in 1.9- and 3.6- fold increase in 
25(OH)D levels, respectively (Table 2). As a consequence, 
a second determination at a median of 6 weeks after 
supplementation start showed a significant increase in 
25(OH)D levels from 14 ± 1.4 ng/mL to 33 ± 1.4 in 81 
patients for whom 25(OH)D levels were available at a 
median of 6 weeks following start of supplementation 
(mean ± SEM, P < 0.0001). (Fig. 3A and B; Table 2). 
Figure 2. 25(OH)D levels in 155 patients with aggressive B- cell lymphomas. (A) Box- plot of 25(OH)D levels. The upper border of the box indicates the 
upper quartile (75th percentile) while the lower border indicates the lower quartile (25th percentile), and the horizontal line in the box the median. 
The vertical lines are the whiskers indicating the upper and lower adjacent values. (B) Distribution of patients according to 25(OH)D levels considered 
to be normal (≥30 ng/mL), insufficient (20–29 ng/mL), or deficient (<20 ng/mL). C) Seasonal variation in 25(OH)D levels were significantly lower in the 
period from April to June (P < 0.001).
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No episodes of hypervitaminosis or hypercalcemia were 
observed. Supplementation resulted in normalization of 
25(OH)D levels in 45/81 patients (56%) (Fig. 3C). In 16 
patients without supplementation, 25(OH)D levels showed 
no significant variation over time (Table 2), while the 
two loading regimens induced normalization of 25(OH)
D levels (>30 ng/mL) in 20/34 (59%) patients with 
insufficient/deficient levels (regimen 2) and in 13/26 
patients (50%) with severely deficient levels (regimen 3).
We compared the supplemented dose of vitamin D3 
to the calculated need, using the formula of Singh et al.
[21], that considers age, body mass index, and albumin 
levels in addition to the baseline 25(OH)D level. The 
median vitamin D need was 642,831 IU for patients with 
Table 1. Patient Characteristics and 25(OH)D levels.
Variables Patients (n) 25(OH)D, ng/mL, (median) P
Total 155 14
Histology
NOS 128 15 0.5
PBML 9 15
TCHR 4 17
Unclassifiable 8 14
Other 6 14
Age
<60 years 60 14 0.8
>60 years 95 15
Gender
Female 89 13 0.5
Male 66 15
Body mass index
<25 kg/m2 90 16 0.05
>25 kg/m2 64 11
Stage
I–II 58 14 0.5
III–IV 97 14
B- symptoms
No 108 15 0.05
Yes 44 9
ECOG
<2 118 16 0.002
≥2 37 10
IPI risk group
Low (0- 1) 40 17 0.1
Intermediate (2- 3) 110 13
High (4- 5) 5 14
IPI age- adjusted
Low (0–1) 78 15 0.1
High (2–3) 77 13
LDH
Normal 72 17 0.0007
Elevated 83 12
Albumin, g/dL
≥4 68 18 0.003
<4 87 12
Hemoglobin, g/dL
≥10 129 15 0.01
<10 26 9
Time period
January–March 56 13 0.01
April–June 36 11
July–September 36 17
October–December 27 19
NOS indicates not otherwise specified; PBML, primary mediastinal large B- cell lymphoma; TCHR, T- cell/histiocyte- rich large B- cell lymphoma; 
Unclassifiable, lymphoma with intermediate characteristics between DLBCL and Burkitt lymphoma. Significant values are indicated in bold.
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insufficient levels, and 937,713 IU for patients with defi-
cient levels. This corresponds to 675,000 IU vitamin D3 
supplemented in regimen 2 and 825,000 IU supplemented 
in regimen 3. Multivariate regression analysis including 
age, albumin levels, body mass index, baseline 25(OH)D 
levels, and supplementation regimen showed that only 
body mass index was a risk factor for not achieving nor-
mal 25(OH)D levels (OR: 1.10, 95% C.I., 1.00–1.24, 
P < 0.05).
Associations of 25(OH)D levels and vitamin 
D3 supplementation with clinical outcome
Treatment response was evaluated in 142/155 patients at 
end of therapy. Response evaluation included PET- CT in 
137 patients. Complete remission was documented in 121 
patients (78%) and partial remission in 10 patients (7%), 
while 11 patients (8%) were considered resistant. Response 
was not evaluable in 13 patients, including 8 (5%) patients 
who died during therapy, and 5 patients who continued 
treatment at other centers. 25(OH)D levels were signifi-
cantly higher in patients with complete remission at end 
of therapy (median 16 ng/mL), when compared to patients 
with partial remission (median 11 ng/mL), resistant disease 
(median 9 ng/mL), or early death (median 8 ng/mL) 
(P = 0.03).
We analyzed the prognostic impact of 25(OH)D levels 
at diagnosis on EFS. Testing 25(OH)D levels as a con-
tinuous variable, we found that each unit increase in 
25(OH)D was associated with a reduction in the risk for 
event (odds ratio 0.959; 95% CI, 0.922–0.998, P = 0.04). 
Using the ROC analysis, we identified the significant cut- 
off point for 25(OH)D levels at 20 ng/ml. Patients with 
lower levels (n = 104) had a significantly worse EFS than 
patients with higher levels (n = 50) (P = 0.01) (Fig. 4A). 
We then adjusted the analysis for the strongest outcome 
predictor in aggressive B- cell lymphomas, the international 
prognostic index (IPI), using multivariate Cox regression 
analysis. 25(OH)D levels < 20 ng/ml and IPI were inde-
pendent prognostic parameters for EFS (Table 3). This 
difference was maintained when the analysis was restricted 
to 116 patients who had been treated with R- CHOP and 
full dose of doxorubicin (P = 0.03) (Fig. 4B). 25(OH)D 
levels proved to be independent from IPI also in this 
patient subgroup (P = 0.04).
We then analyzed the prognostic impact of 25(OH)
D levels following oral supplementation in patients 
treated with R- CHOP and full- dose doxorubicin. Patients 
with 25(OH)D levels in the normal range following 
supplementation (n = 36) had a significantly better 
EFS than patients with persistently lower than normal 
25(OH)D levels (n = 32) (P = 0.02) (Fig. 5). Adjusting 
for IPI in multivariate Cox regression analysis, persis-
tently low 25(OH)D was a risk factor for inferior EFS 
of borderline significance (HR 4.68; 95% C.I., 0.95–23.09; 
P = 0.06).
Discussion
We show here that 25(OH)D levels can be rapidly and 
safely normalized in at least half of the patients with 
aggressive B- cell lymphomas using a daily supplementation 
regimen with vitamin D3 (cholecalciferol). In addition, 
our study provides the first, though preliminary evidence 
that response to vitamin D supplementation may improve 
outcome in patients receiving conventional rituximab- 
containing chemotherapy. Finally, our observations confirm 
that vitamin D deficiency/insufficiency is frequent in both 
young and elderly patients with aggressive B- cell lympho-
mas, and correlate with both host- related and disease- 
related characteristics as well as with inferior outcome. 
We observed a seasonal variation according to sunlight 
exposure, with the lowest and highest levels before and 
after the summer, respectively.
Table 2. Variation in 25(OH)D levels during therapy
Regimen1
Number of 
Patients2
25(OH)D at 
diagnosis, 
ng/mL 
(mean)
25(OH)D 
during 
therapy ng/
mL (mean)
Number of 
Patients with 
normal 25(OH)
D at diagnosis
Number of 
Patients with 
normal 25(OH)
D during 
therapy
Fold 
Difference 
vs. baseline 
(median)
Fold 
Difference vs. 
baseline 
(95% CI) P 3
0 16/39 23.0 19.4 6/16 (%) (38%) 3/16 (19%) 1.10 0.57- 1.38 0.3
1 21/35 25.6 34.8 6/21 (29%) 12/21 (57%) 1.31 0.99- 2.40 0.05
2 34/52 16.8 35.1 0/34 (0%) 20/34 (59%) 1.94 1.71- 2.22 <0.0001
3 26/29 9.5 30.9 0/26 (0%) 13/26 (50%) 3.59 2.54- 4.23 <0.0001
1Regimen 0: no vitamin D supplementation; regimen 1: Vitamin D 25,000 IU once weekly; regimen 2: Vitamin D 25,000 IU daily for 1 week, followed 
by vitamin D 25,000 IU once weekly; regimen 3: Vitamin D 25,000 IU daily for 2 weeks followed by vitamin D 25,000 IU once weekly. 
2Number of patients with a second Vitamin D level during therapy/total number of patients in the group of regimen of supplementation. 
3Comparison of 25(OH)D levels at start and during therapy using paired t- test. Significant p-values (<0.05) are indicated in bold.
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25(OH)D levels were normal in 12% of patients in 
the present series. This is a considerably higher fraction 
than the <1% reported in the study from Bittenbring 
et al. in elderly patients with DLBCL from Germany [4]. 
The median level was 14 ng/mL in our patient series. 
This appears to be similar to the median 25(OH)D con-
centration of 16 ng/mL reported for individuals who 
participated in the InCHIANTI study, a population- based, 
prospective cohort study on aging in Tuscany, a region 
in central Italy [22]. In a population of 294 obese indi-
viduals referred to a Metabolic Unit in Rome, only 19% 
had 25(OH)D levels in the normal range (>30 ng/mL) 
and the mean 25(OH)D level was 16 ng/mL, with sig-
nificant variation between winter and summer [23]. 
25(OH)D levels appear to be lower in the Mediterranean 
area with respect to Northern Europe and North America 
[24]. A careful case–control study matching for gender, 
age, season, and geographical origin will be needed to 
address the question, whether 25(OH)D levels in patients 
with DLBCL are lower than in the general population.
Associations between 25(OH)D levels and some patient 
characteristics are not unexpected. Poor performance status 
is associated with reduced physical activity and sunlight 
exposure, two factors that are well known to influence 
25(OH)D levels [20]. Associations with low albumin levels 
could probably indicate lower dietary vitamin D intake 
or reduced hydroxylation in the liver, the major site for 
25(OH)D generation. Moreover, we observed associations 
with parameters of disease activity such as LDH and pres-
ence of B- symptoms. The mechanism underlying this 
Figure 3. Variation in 25(OH)D levels during supplementation. (A) in patients supplemented with vitamin D3 according to regimen 1, (B) patients 
supplemented with regimen 2. (C) Proportion of patients with 25(OH)D levels during supplementation in the normal (≥30 ng/mL), insufficient 
(20–29 ng/mL), and deficient (<20 ng/mL) range. 25(OH)D levels were measured in 81 patients.
A
C
B
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association is unclear. B- symptoms are the clinical sign 
of inflammatory cytokine production by the tumor. In a 
population study, lower 25(OH) D levels have been asso-
ciated with higher levels of IL- 6 [25]. In the same line, 
the inverse association between 25(OH)D and hemoglobin 
is not unexpected. Recent data indicate that expression 
of the iron- regulatory peptide hepcidin can be modulated 
by vitamin D, pointing to a role for vitamin D in the 
development of anemia of chronic inflammation [26–28]. 
We have previously shown that the IL- 6/hepcidin axis is 
frequently active in patients with Hodgkin and aggressive 
B- cell lymphomas [29,30].
We confirm here the prognostic value of baseline 25(OH)
D levels on outcome, that has been previously reported 
in elderly patients with aggressive B- cell lymphoma [4]. 
In a retrospective analysis, we determined that patients 
with 25(OH)D levels below 20 ng/mL had a significantly 
lower EFS. In the German study, the threshold value was 
8 ng/mL, while in the study on follicular lymphoma, the 
prognostically relevant threshold varied between patients 
from France (10 ng/mL) and the United States (20 
ng/mL) [5]. Further studies are needed to clarify whether 
these variable thresholds reflect geographical or ethnic 
differences, and to elucidate the role of other factors such 
as climate, diet, or other lifestyle habits. The limited 
number of patients in our study did not allow for mul-
tiple adjustments of the survival analysis for the confound-
ing patient characteristics. We therefore cannot exclude 
that 25(OH)D level is a surrogate marker for the health 
status of the patient.
As there is a good biological rationale for the role of 
vitamin D in improving the antibody- dependent antitumor 
macrophage activity [14], we supplemented vitamin D in 
patients with low 25(OH)D levels. We chose cholecalciferol 
(vitamin D3), as this form appears to be more effective 
than vitamin D2 [18, 31]. We developed a vitamin D 
supplementation regimen, including a loading phase 
according to the baseline serum 25(OH)D level. Our 
schedules appear to be safe as we did not observe toxic 
effects or hypercalcemia, and 25(OH)D levels never 
exceeded the normal range, although the vitamin D3 dose 
during maintenance corresponded to 3570 IU/day, which 
is higher than the recommended dose of up to 2000 IU/
day. However, a limit of 10,000 IU/day has been proposed 
as the no adverse effect limit in healthy subjects [32] and 
high vitamin D3 daily doses up to 10,000 IU for 4 months 
were reported to be safe in patients with breast cancer 
[33]. Moreover, vitamin D toxicity has been reported to 
start with chronic consumption of approximately 
40,000 IU/day [34]. The introduction of an initial loading 
phase resulted in a more significant increase in 25(OH)
D levels after a median of 6 weeks compared to the 
weekly supplementation regimen. Nevertheless, still nearly 
half of the patients continued to have lower than normal 
25(OH)D levels. This may suggest that patients undergo-
ing immunochemotherapy, including corticosteroids, may 
be in need of higher vitamin D3 intake [35]. In the same 
line with our results, 44% of patients with lung cancer 
who received a daily loading regimen with 20,000 IU 
Table 3. Multivariate analyses of event- free survival in 154 patients (Cox regression).
Variable HR 95% C.I. P**
25(OH)D level at diagnosis  
<20 ng/mL vs. ≥20 ng/mL
2.88 1.20–6.90 0.02
IPI 
3–5 vs. 0–2
2.97 1.47–56.00 0.002
HR, hazard ratio, C.I., confidence interval. ** P-values <0.05 are considered significant
Figure 4. Event- free survival in patients with aggressive B- cell lymphoma 
according to 25(OH)D levels at diagnosis. (A) Group A (n = 50 patients) 
had 25(OH)D levels ≥ 20 ng/mL at diagnosis, group B (n = 104 patients) 
had 25(OH)D levels <20 ng/mL at diagnosis. The survival difference is 
statistically significant (P = 0.01). (B) The survival analysis was restricted 
to 116 patients treated with R- CHOP containing full dose of doxorubicin, 
according to 25(OH)D levels. Group A (n = 43 patients) had 25(OH)D 
levels ≥20 ng/mL at diagnosis, group B (n = 73 patients) had 25(OH)D 
levels <20 ng/mL at diagnosis. The difference is statistically significant 
(P = 0.03).
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vitamin D3 failed to achieve the target 25(OH)D level at 
an early control at 3 weeks [36]. Very recently, an experi-
ence with weekly supplementation with 50,000 IU vitamin 
D3 in 71 lymphoma patients with vitamin D insufficiency 
defined as 25(OH)D levels <25 ng/mL has been reported 
[37]. At 12 weeks all but one patient achieved 25(OH)
D levels >25 ng/mL. At difference to our study, the second 
determination of the 25(OH)D level was performed later, 
when patients had already received a higher amount of 
vitamin D3 (600.000 IU).
We do not have a direct method to measure compli-
ance. However, the second determination of 25(OH)D 
levels during supplementation might serve as an indirect 
indicator of compliance. As patients without supplementa-
tion did not show any significant change or a tendency 
for a decrease in the 25(OH)D level, and patients with 
regimen 2 and 3 generally showed significant increases 
in 25(OH)D levels (Table 2), we suspect that 4/60 (7%) 
patients in whom regimen 2 or 3 was prescribed and 
who showed a decrease and another 6/60 (10%) patients 
who showed only a slight increase that remained in the 
95% CI of change in the second 25(OH)D determination 
of patients who did not receive substitution might not 
have been fully compliant. We estimate compliance to 
be around 83–93%.
The most significant factor predicting normalization of 
25(OH)D levels was BMI. Adjustment of vitamin D3 dos-
ing according to the BMI, by increasing the dose for 
patients with higher BMI, might be a strategy to normalize 
vitamin D in a greater proportion of patients [38]. An 
association between BMI and 25(OH)D levels has been 
reported in a small series of lymphoma patients [39]. 
The higher need in patients with increased BMI is due 
to the fat- soluble nature of vitamin D and sequestration 
into adipose tissue. Higher single doses during the loading 
phase may be needed in these patients. Single doses of 
up to 200,000 IU have been reported to be safe and 
effective [40]. However, there is evidence that very high 
doses may saturate hydroxylation reactions, thereby reduc-
ing the efficiency to generate 25(OH)D within a given 
period of time [41].
To address the question whether vitamin D3 supple-
mentation resulted in clinical benefit, we analyzed event- free 
survival according to the 25(OH)D level that had been 
achieved by supplementation. Patients with normal 25(OH)
D levels after supplementation had a significant better 
event- free survival when compared to patients with per-
sistently low 25(OH)D levels, independently of the IPI score. 
To the best of our knowledge, this is the first study show-
ing that response to vitamin D supplementation is associated 
with improved outcome in patients with DLBCL treated 
with immunochemotherapy. We cannot exclude that factors 
that determine the patient’s ability to normalize 25(OH)
D levels are the underlying mechanism for this association. 
Further studies, and ideally a randomized study on sup-
plementation would be needed to confirm our observations. 
However, a randomized study might be difficult to perform, 
as detection of vitamin D deficiency is per se an indication 
to intervene to correct the deficiency.
Our supplementation led to 25(OH)D levels in the 
lower normal or insufficient range, and levels exceeded 
60 ng/mL only in 5/81 (6%) patients. Serum concentra-
tions that are considered optimal vary according to the 
effect of vitamin D on various tissues. Target 25(OH)D 
levels for optimal calcium absorption are lower when 
compared to other health outcomes [15, 25, 42]. 
Parathyroid hormone (PTH) levels increase with vitamin 
D deficiency and might be an important indicator for 
the bone remodeling. It is not clear whether PTH levels 
might be also a surrogate marker for other functional 
consequences of vitamin D deficiency. The optimal 25(OH)
D range for the stimulatory effect on the immune system 
has not been defined. We therefore do not know whether 
more intense supplementation resulting in higher 25(OH)
D levels might increase the clinical benefit. Future studies 
are needed to determine the target 25(OH)D concentra-
tion necessary to optimize the biological effects of the 
antitumor macrophage activity.
We stopped vitamin D replacement at end of immu-
notherapy. It is unclear whether prolongation of vitamin 
D supplementation beyond anti- lymphoma therapy could 
have an additional benefit on survival. Another area of 
interest for future studies will be whether genetic poly-
morphism in genes coding for proteins involved in the 
vitamin D pathway will modulate response to supplemen-
tation. These proteins include the vitamin D- binding 
Figure 5. Event- free survival in patients with aggressive B- cell lymphoma 
according to 25(OH)D levels following supplementation. The survival 
analysis was restricted to 68 patients treated with R- CHOP containing 
full dose of doxorubicin, according to 25(OH)D levels. Group A (n = 36 
patients) had normal (≥30 ng/mL), and group B lower than normal 
(<30 ng/mL) 25(OH)D levels after loading phase. The survival difference 
is statistically significant (P = 0.02).
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protein (DBP), that facilitates the transport of vitamin D 
metabolites in blood, the vitamin D receptor (VDR), a 
ligand- dependent transcription factor, and enzymes of the 
cytochrome family that activate and inactivate vitamin D 
[43]. Many of the genes involved in the vitamin D path-
way are highly polymorphic. In particular, more than 60 
polymorphism have been described for the VDR gene 
[44]. Polymorphism has been associated with plasma levels, 
bioavailability, and function of vitamin D [43].
In conclusion, our study provides further evidence that 
vitamin D is a prognostically relevant and easily modifi-
able biomarker in aggressive B- cell NHL. Further studies 
are needed to confirm our observations on the safety of 
vitamin D supplementation and its impact on treatment 
outcome.
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